Hamilton Depression Rating Scale (HDRS-17)

Abstract

The Hamilton Depression Rating Scale (HDRS or HAM-D) is a widely utilized, clinician-administered instrument designed to quantify the severity of symptoms experienced by patients with depression. Developed by Max Hamilton in 1960, the most common version, the HDRS-17, consists of 17 items that assess core dimensions of depressive illness, including affective, cognitive, somatic, and behavioral manifestations. Although originally a 29-item scale, the 17-item version is the standard for clinical trials and routine clinical practice, providing a reliable measure for monitoring treatment efficacy and assessing changes in symptom severity over time. It is crucial to note that the HDRS-17 is an assessment tool for severity and response, not a primary diagnostic instrument.

Keywords

Hamilton Rating Scale for Depression, HDRS-17, HAM-D, Depression severity, Affective symptoms, Somatic symptoms, Clinician-rated scale, Psychometrics, Treatment outcome.

Authors

Max Hamilton.

Purpose

The primary purpose of the Hamilton Depression Rating Scale (HDRS-17) is to provide a standardized, objective measure of the depth and intensity of depressive symptomatology in individuals already diagnosed with a depressive disorder. It is highly valued in psychiatric research, particularly in randomized controlled trials, where it serves as the benchmark outcome measure for evaluating the efficacy of pharmacological agents and psychotherapeutic interventions.

Beyond research, the HDRS-17 is used in clinical settings to track the patient’s progress during treatment, allowing clinicians to adjust therapeutic strategies based on quantitative changes in score. The scale helps differentiate between mild, moderate, and severe states of depression, although consensus scoring thresholds (0-6: None; 7-17: Mild; 18-24: Moderate; >24: Severe) should be interpreted cautiously and supported by clinical judgment.

Construct

The HDRS-17 measures the severity of the depressive syndrome, encompassing a wide range of symptoms categorized into four major domains. These dimensions include:

• Affective Symptoms: Core mood disturbances such as sadness, hopelessness, and feelings of worthlessness or guilt.
• Cognitive Symptoms: Difficulties related to thinking, concentration, indecisiveness, and the presence of suicidal ideation.
• Somatic (Physical) Symptoms: Vegetative signs including sleep disturbance (early, middle, and late insomnia), loss of appetite, fatigue, and general bodily complaints.
• Behavioral Symptoms: Observable phenomena like social withdrawal, loss of interest in activities, and changes in psychomotor retardation or agitation.

The scale operates on a dimensional model, viewing depression as a continuum of severity rather than a purely categorical diagnosis. The scoring system reflects this continuum, with higher cumulative scores corresponding to greater clinical impairment.

Validity

The HDRS is recognized for its strong psychometrics, demonstrating robust validity across numerous studies since its inception. It exhibits good discriminant validity, meaning it effectively distinguishes between depressed patients and non-depressed individuals, and often shows sensitivity to change over time, which is critical for measuring treatment response in clinical trials.

The scale’s criterion validity is high, correlating well with other established measures of depressive severity. Its enduring use as the “gold standard” in clinical trials further attests to its recognized content and predictive validity in pharmacological research settings. However, some limitations exist regarding its specificity, as it includes items related to anxiety, which may inflate scores in patients with comorbid conditions.

Reliability

The HDRS-17 demonstrates strong reliability metrics essential for a standardized clinical tool. It possesses high internal consistency, indicating that the individual items within the scale measure the same underlying construct of depression severity. Furthermore, studies consistently report good test-retest reliability, affirming that the scale yields consistent results when administered to the same patient under stable clinical conditions over short intervals.

However, as a clinician-rated scale, inter-rater reliability is a crucial factor. Variability in scores can occur if raters are not rigorously trained. Standardized training protocols, often involving structured interview guides (like the SIGH-D), are essential to maintain consistency and ensure that the scale produces reliable and replicable results across different clinical sites or assessors.

Factor Analysis

Factor analytic studies of the HDRS-17 have historically yielded varied results, reflecting the heterogeneity of the depressive syndrome itself. Generally, research suggests that the HDRS-17 is not strictly unidimensional. Common factor solutions typically extract between three and five factors, often including:

1. A central Core Depressive Factor (Mood, Guilt, Suicide).
2. A Somatic/Sleep Factor (Insomnia, Gastrointestinal, General Somatic symptoms).
3. An Anxiety/Agitation Factor (Psychological and Somatic Anxiety, Agitation).

The variability in factor structure across different patient populations (e.g., inpatients vs. outpatients) highlights the need for clinicians and researchers to consider specific symptom clusters when interpreting total scores, especially when comparing treatment effects across different domains of depression.

Instrument

Test Type: Clinician-rated scale (Hetero-report). The assessment is based on a structured or semi-structured interview conducted by a trained professional.

Format: Semi-structured interview guide. The HDRS-17 variant scores 17 items, using 3-point (0-2) or 5-point (0-4) Likert scales.

Language Available: Widely translated and validated in numerous languages globally.

Population Group: Clinical populations diagnosed with Major Depressive Disorder (MDD) or other depressive syndromes.

Age Group: Typically used for adults (18+), though adapted for other age groups.

Population Details: Used extensively in psychiatric inpatient and outpatient settings, particularly in contexts requiring precise measurement of symptom change, such as clinical trials for psychotropic medications.

Test Methodology: The clinician rates the patient on each item based on interview data and clinical observation over the preceding week. Total scores range from 0 to 52 for the HDRS-17 version.

Keywords

HAMD-17, Max Hamilton, Severity assessment, Clinical trial endpoint, Clinician interview, Psychometrics, Symptomology.

Authors

Author ORCID Identifier: N/A

Affiliation Email addresses: N/A

Correspondence Address: N/A

Permissions & Fee and Test Year

The scale was first published in 1960. It is now generally considered to be in the public domain for research and clinical use, although specific structured interview guides developed later (such as SIGH-D) may require licensing or permission from the developers or publishers.

The original publication detailing the scale is: Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry, 23, 56-62.

The instrument documentation can be found online, for example, via: http://www.springer.com/978-1-58829-966-6

Reference’s

• Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry, 23, 56-62.
• Guy, W. (1976). ECDEU Assessment Manual for Psychoactive Drugs. Rockville, MD: National Institute of Mental Health.
• Zimmerman, M., & Coryell, W. (1989). Diagnostic efficiency of the Hamilton Depression Rating Scale. Archives of General Psychiatry, 46, 796-804.
• Hamilton M: Hamilton rating scale for Depression (Ham-D), in Handbook of psychiatric measures. Washington DC, APA, 2000, pp 526–8.
• Williams JB: A structured interview guide for the Hamilton depression rating scale. Arch Gen Psychiatry 1988; 45:742–7.
• Muller MJ, Dragicevic A: Standardized rater training for the Hamilton Depression Rating Scale (HAMD-17) in psychiatric novices. J Affective Dis 2003; 77:65–9.
• Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry, 2003; 54:573–83.
• Kobak KA, Lipsitz JD, Feiger A: Development of a standardized training program for the Hamilton Depression Scale using internet-based technologies: results from a pilot study. J Psychiatric Res 2003; 37:509–15.
• Bagby RM, Ryder AG, Schuller DR, Marshall MB: The Hamilton depression rating scale: has the gold standard become a lead weight? Am J Psychiatry 2004; 161:2163–77.

Items of the Hamilton Depression Rating Scale (HDRS-17)

IMPORTANT: The following scale items must be preserved in their original language and must not be changed in any way.

1- Depressed Mood (sadness‚ hopeless‚ helpless‚ worthless)

0. Absent

1. These feeling states indicated only on questioning

2. These feeling states spontaneously reported verbally

3. Communicates feeling states non-verbally – i.e.‚ through facial expression‚ posture‚ voice‚ and tendency to weep

4. Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal and non-verbal communication

2- Feelings of Guilt

0. Absent.

1. Self reproach‚ feels he has let people down

2. Ideas of guilt or rumination over past errors or sinful deeds

3. Present illness is a punishment. Delusions of guilt

4. Hears accusatory or denunciatory voices and/or experiences threatening visual hallucinations

3- Suicide

0. Absent

1. Feels life is not worth living

2. Wishes he were dead or any thoughts of possible death to self

3. Suicidal ideas or gesture

4. Attempts at suicide (any serious attempt rates 4)

4- Insomnia Early

0. No difficulty falling asleep

1. Complains of occasional difficulty falling asleep – i.e.‚ more than 1/2 hour

2. Complains of nightly difficulty falling asleep

5- Insomnia Middle

0. No difficulty

1. Patient complains of being restless and disturbed during the night

2. Waking during the night – any getting out of bed rates 2 (except for purposes of voiding)

6- Insomnia Late

0. No difficulty

1. Waking in early hours of the morning but goes back to sleep

2. Unable to fall asleep again if he gets out of bed

7- Work and Activities

0. No difficulty

1. Thoughts and feelings of incapacity‚ fatigue or weakness related to activities‚ work or hobbies

2. Loss of interest in activity‚ hobbies or work – either directly reported by patient‚ or indirect in listlessness‚ indecision and vacillation (feels he has to push self to work or activities)

3. Decrease in actual time spent in activities or decrease in productivity

4. Stopped working because of present illness

8- Retardation: Psychomotor (slowness of thought and speech; impaired ability to concentrate; decreased motor activity)

0. Normal speech and thought

1. Slight retardation at interview

2. Obvious retardation at interview

3. Interview difficult

4. Complete stupor

9- Agitation

0. None

1. Fidgetiness

2. Playing with hands‚ hair‚ etc.

3. Moving about‚ can’t sit still.

4. Hand wringing‚ nail biting‚ hair-pulling‚ biting of lips.

10-Anxiety (psychological)

0. No difficulty

1. Subjective tension and irritability

2. Worrying about minor matters

3. Apprehensive attitude apparent in face or speech

4. Fears expressed without questioning

11-Anxiety Somatic: Physiological concomitants of anxiety (i.e.‚ effects of autonomic over activity‚ “butterflies‚” indigestion‚ stomach cramps‚ belching‚ diarrhea‚ palpitations‚ hyperventilation‚ paresthesia‚ sweating‚ flushing‚ tremor‚ headache‚ urinary frequency). Avoid asking about possible medication side effects (i.e.‚ dry mouth‚ constipation)

0. Absent

1. Mild

2. Moderate

3. Severe

4. Incapacitating

12-Somatic Symptoms (gastrointestinal)

0. None.

1. Loss of appetite but eating without encouragement from others. Food intake about normal

2. Difficulty eating without urging from others. Marked reduction of appetite and food intake.

13-Somatic Symptoms General

0. None

1. Heaviness in limbs‚ back or head. Backaches‚ headache or muscle aches. Loss of energy and fatigability.

2. Any clear-cut symptom rates “2”

14-Genital Symptoms (symptoms such as loss of libido; impaired sexual performance; menstrual disturbances)

0. Absent

1. Mild

2. Severe

15-Hypochondriasis

0. Not present

1. Self-absorption (bodily)

2. Preoccupation with health

3. Frequent complaints‚ requests for help‚ etc.

4. Hypochondriacal delusions

16- Loss of Weight

0. No weight loss

1. Probable weight loss associated with present illness

2. Definite (according to patient) weight loss

3. Not assessed

17- Insight

0. Acknowledges being depressed and ill

1. Acknowledges illness but attributes cause to bad food‚ climate‚ overwork‚ virus‚ need for rest‚ etc.

2. Denies being ill at all